

# 4CPS-203 COMPARISON OF PIRFENIDONE VERSUS NINTEDANIB IN IDIOPATHIC PULMONARY FIBROSIS

E. HERRANZ BAYO, I. AGUILÓ LAFARGA, J. PERALES PASCUAL, A. LÓPEZ PÉREZ, H. NAVARRO AZNAREZ, M. URIARTE PINTO  
MIGUEL SERVET UNIVERSITY HOSPITAL, HOSPITAL PHARMACY, ZARAGOZA, SPAIN.

## BACKGROUND AND IMPORTANCE

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disease.

Antifibrotic drugs (pirfenidone and nintedanib) is characterized by a high incidence of adverse effects (AE) that together with the progression of the disease make therapeutic persistence difficult.

## AIM AND OBJECTIVES

Compare pirfenidone and nintedanib in terms of:

- ❖ Effectiveness
- ❖ Safety
- ❖ Durability of treatment

## MATERIALS AND METHODS

Retrospective observational study of patients treated with pirfenidone and / or nintedanib from November / 2012 to May / 2021, conducted in a tertiary hospital.

### Variables collected

- Age
- Sex
- Forced vital capacity (FVC)
- Duration of treatment
- Dose
- Reason for suspension
- Adverse effects
- Adherence


**Effectiveness** was measured as a <10% reduction in FVC at 12 and 24 months.

Data sources: Outpatient Dispensing program and clinical history. Analysis with SPSS Statistics 21®.

## RESULTS

	PIRFENIDONE (N=83)	NINTEDANIB (N=58)	P-value
Percentage men(%)	76	69	
Age (mean)	73	72	
Dose reductions(%)	18	38	<b>&lt;0.05</b>
Switched drugs(%)	17	26	0.19
Adverse effects(%)	45	43	
Adherence(%)	92	87	

### DURABILITY ANALYSIS BY KAPLAN-MEIER



### PROGRESSION

The percentage of patients who progressed

- Pirfenidone: **38%**
- Nintedanib: 23%

p= 0.13

The speed of progression (within the first 12 months)

- Pirfenidone: **73%**
- Nintedanib: 38%

p<0.05

### REASONS FOR SUSPENSION

#### PIRFENIDONE

- ❖ 23/45 death
- ❖ 19/45 AE
- ❖ 2/45 change of hospital
- ❖ 1/45 lung transplantation

#### NINTEDANIB

- ❖ 9/23 death
- ❖ 8/23 AE
- ❖ 3/23 change of hospital
- ❖ 3/23 anticoagulant treatment

## CONCLUSION AND RELEVANCE

Pirfenidone and nintedanib have a very similar safety and durability profile, it seems that with pirfenidone a greater number of patients progress and do so faster, however larger sample size studies would be necessary to achieve statistical significance.